Termination of Registration of a Class of Security Under Section 12(b) (15-12b)
July 21 2017 - 5:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION
OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES
EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS
UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number
001-34566
China Biologic Products, Inc.*
(Exact name of registrant as specified
in its charter)
18th Floor, Jialong International Building
19 Chaoyang Park Road
Chaoyang District, Beijing
People’s Republic of China
(Address, including zip code, and telephone
number, including area code, of registrant’s principal executive offices)
Common Stock, $0.0001 par value per share
Preferred Share Purchase Rights
(Title of each class of securities covered
by this Form)
None*
(Titles of all other classes of securities
for which a duty to file reports under section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate
rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1)
|
x
|
Rule 12g-4(a)(2)
|
¨
|
Rule 12h-3(b)(1)(i)
|
x
|
Rule 12h-3(b)(1)(ii)
|
¨
|
Rule 15d-6
|
¨
|
Approximate number of holders of record as of the certification
or notice date: 0
*
Explanatory Note
* Effective July 21, 2017, China Biologic
Products, Inc., a Delaware corporation (the “Predecessor”), completed the redomicile merger (the “Redomicile
Merger”) to reorganize itself as a Cayman Islands company, as contemplated by the agreement and plan of merger dated as of
April 28, 2017 (the “Merger Agreement”) by and among the Predecessor and China Biologic Products Holdings, Inc., an
exempted company incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of the Predecessor (the “Successor”).
Pursuant to the Merger Agreement, each issued and outstanding share of the common stock of the Predecessor was converted into the
right to receive one ordinary share of the Successor. The Redomicile Merger constitutes a succession for purpose of Rule 12g-3(a)
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This Form 15 relates solely to the reporting
obligations of the Predecessor under the Exchange Act, and does not affect the reporting obligations of the Successor under the
Exchange Act.
Pursuant to the requirements of the Securities Exchange Act
of 1934, as amended, China Biologic Products Holdings, Inc., as successor to China Biologic Products, Inc., has caused this certification/notice
to be signed on its behalf by the undersigned duly authorized person.
Date:
|
July 21, 2017
|
By:
|
/s/ David (Xiaoying)
Gao
|
|
|
Name:
|
David (Xiaoying) Gao
|
|
|
Title:
|
Chief Executive Officer
|
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From Apr 2024 to May 2024
China Bioligic Products (NASDAQ:CBPO)
Historical Stock Chart
From May 2023 to May 2024